Get started
Work

Supplemental Figure S2 from Tusamitamab Ravtansine in Patients with Advanced Solid Tumors: Phase I Study of Safety, Pharmacokinetics, and Antitumor Activity Using Alternative Dosing Regimens

Year: 2023
Type: supplementary-materials
Abstract: Tusamitamab ravtansine area under the curve by dose level
DOI: 10.1158/2767-9764.24043020.v1
Authors: Josep Tabernero, Philippe L. Bedard, Yung-Jue Bang, Maria Vieito, Min-Hee Ryu, Nathalie Fagniez, Mustapha Chadjaa, Christine Soufflet, Nina Masson, Anas Gazzah
Language: English
Field: Medicine
Open Access status: gold
OpenAlex ID: W4386225205
Cites:
Cited by:
Related to: 10